ArticleScientific reports2025
Clinicopathological characteristics and prognostic analysis of multifocal/multicentric breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07677956 (Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer: A Prospective Cohort Study
Who cites it
1 citing paper in PubMed.
- Characteristics of Breast Cancer Patients in Northeastern Iran: A Retrospective Cohort Study.Breast cancer : basic and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To explore the correlation between the clinicopathological characteristics and prognosis of multifocal/multicentric breast cancer (MMBC), the clinicopathological data of 262 patients with multifocal/multicentric breast cancer and 1,745 patients with unifocal breast cancer (UFBC) were retrospectively collected and followed up. The analysis of the differences in clinicopathological characteristics showed that compared with patients with UFBC, patients with MMBC had a higher proportion of those aged ≤ 40 years (P < 0.001), premenopausal status (P < 0.001), "other types of invasive carcinoma" in histological types (P < 0.001), negative HER2 expression (P = 0.010), and absence of nerve invasion (P < 0.001), a lower proportion of those with a lower histological grade (P < 0.001), receiving chemotherapy after surgery (P = 0.018), and receiving targeted therapy after surgery (P = 0.023). The results of Survival analysis showed that there was no statistically significant difference in disease-free Survival (DFS) between the two groups of people (P = 0.199), while the difference in Overall Survival (OS) was statistically significant (P = 0.003). This may be related to the higher lymph node metastasis rate and tumor burden in MMBC patients. The clinicopathological characteristics and prognosis analysis of MMBC showed that menopause and clinical stage III were independent risk factors affecting DFS (P < 0.05), and menopause was an independent risk factor affecting OS (P = 0.010). In conclusion, this study confirmed that MMBC has different clinicopathological features from UFBC, which may be related to the prognostic differences between the two. Additionally, for MMBC patients who have reached menopause and have a higher clinical stage, more comprehensive assessment and individualized treatment are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.